Silence Therapeutics (SLN)
NASDAQ:SLN
Top Page
Silence Therapeutics
(NASDAQ:SLN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.00
▲(0.00% Upside)
Action:ReiteratedDate:03/25/26
The score is primarily held down by very weak financial performance (revenue collapse, widening losses, persistent cash burn, and negative equity). Technicals also point to a broader downtrend despite near-oversold readings. Valuation provides limited support due to loss-driven negative P/E and no dividend, while corporate events are mixed with a significant partnership/program setback offsetting some pipeline progress.
Positive Factors
Proprietary RNAi delivery platform
Ownership of a proprietary RNAi delivery/chemistry platform (mRNAi GOLD) is a durable competitive asset. It supports multiple programs, enables partnerships and licensing, and can drive recurring non-dilutive revenue streams and higher deal value versus one-off assets over the medium term.
Negative Factors
High and persistent cash burn
Sustained negative operating and free cash flow of ~-$62M in 2025 indicates heavy monthly financing needs. Over months this erodes runway, forces dilutive equity raises or onerous deal terms, and can constrain consistent program funding and long-term R&D planning.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary RNAi delivery platform
Ownership of a proprietary RNAi delivery/chemistry platform (mRNAi GOLD) is a durable competitive asset. It supports multiple programs, enables partnerships and licensing, and can drive recurring non-dilutive revenue streams and higher deal value versus one-off assets over the medium term.
Read all positive factors
Silence Therapeutics (SLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$283.64M
Dividend YieldN/A
Average Volume (3M)101.05K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees116
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding47,233,948
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue496.66
Enterprise Value/Gross Profit807.08
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$34.75Price Target Upside479.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$8.46M
Silence Therapeutics Business Overview & Revenue Model
Company Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi...
How the Company Makes Money
Silence Therapeutics primarily makes money through (1) collaboration and licensing arrangements with larger pharmaceutical/biotechnology companies and (2) funding related to its partnered R&D activities, with (3) potential future revenue from comm...
Silence Therapeutics Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted positive clinical trial results for zerlasiran and divesiran, revenue growth, and an extended cash runway. However, the termination of the Hansoh Pharma collaboration and the delay of the zerlasiran Phase 3 study due to the need for a partner were significant challenges mentioned.Positive Updates
Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Negative Updates
Hansoh Pharma Collaboration Termination
Hansoh Pharma opted not to pursue further development under the collaboration, resulting in the company regaining rights to three undisclosed preclinical liver targets.
Read all updates
Q4-2024 Updates
Positive
Negative
Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Read all positive updates
Company Guidance
During the call, Silence Therapeutics provided guidance on several key metrics for their future operations. The company reported $43.3 million in revenues for 2024, an increase from $31.6 million in 2023, largely due to collaboration arrangements. They ended 2024 with $147.3 million in cash, cash equivalents, and short-term investments. Silence announced they would only initiate the Phase 3 outcomes study for zerlasiran, their siRNA for high Lp(a), once a partner is secured, which extends their cash runway into 2027. Additionally, they are prioritizing investment in programs targeting rare conditions, like divesiran for polycythemia vera (PV), which has received orphan drug designation in both the EU and US. The company also plans to commence a Phase 1 study of SLN548 targeting complement factor B in the second half of 2025. Silence transitioned to a U.S. domestic issuer status, moving from IFRS to U.S. GAAP, which resulted in a net loss decrease to $45.3 million in 2024 from $54.2 million in 2023.Silence Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 559.00K | 43.26M | 25.38M | 21.66M | 12.41M |
| Gross Profit | 344.00K | 31.45M | 15.06M | 8.19M | 4.96M |
| EBITDA | -89.20M | -48.99M | -49.78M | -60.44M | -45.42M |
| Net Income | -88.61M | -45.31M | -43.27M | -50.33M | -39.41M |
Balance Sheet | |||||
| Total Assets | 131.44M | 202.63M | 119.45M | 107.50M | 96.19M |
| Cash, Cash Equivalents and Short-Term Investments | 85.11M | 147.33M | 68.79M | 71.14M | 73.54M |
| Total Debt | -160.00K | 117.00K | 346.00K | 446.00K | 137.00K |
| Total Liabilities | 69.14M | 68.61M | 97.45M | 85.43M | 87.67M |
| Stockholders Equity | 62.30M | 134.02M | 21.99M | 22.07M | 8.53M |
Cash Flow | |||||
| Free Cash Flow | -62.33M | -67.85M | -39.40M | -57.59M | 7.39M |
| Operating Cash Flow | -62.27M | -67.64M | -39.35M | -57.04M | 9.19M |
| Investing Cash Flow | -35.70M | -21.97M | 16.43M | -20.50M | 11.71M |
| Financing Cash Flow | 11.16K | 142.09M | 25.16M | 52.58M | 41.45M |
Silence Therapeutics Technical Analysis
Positive
6.00
Price Trends
5.52
Positive
5.81
Positive
5.82
Positive
Market Momentum
>-0.01
Negative
54.10
Neutral
80.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Positive. The current price of 6 is above the 20-day moving average (MA) of 5.83, above the 50-day MA of 5.52, and above the 200-day MA of 5.82, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.10 is Neutral, neither overbought nor oversold. The STOCH value of 80.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLN.
Silence Therapeutics Risk Analysis
Silence Therapeutics disclosed 61 risk factors in its most recent earnings report. Silence Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Silence Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $288.67M | 3.92 | 53.18% | ― | ― | ― | |
47 Neutral | $780.09M | -0.19 | 72.70% | ― | ― | -1072.48% | |
44 Neutral | $283.64M | -3.24 | -300.94% | ― | ― | ― | |
44 Neutral | $148.77M | -3.72 | -424.76% | ― | ― | 82.23% | |
43 Neutral | $154.69M | -8.62 | 25.65% | ― | ― | 18.82% |
* Healthcare Sector Average
SLN
Silence Therapeutics
6.12
3.32
118.57%
GALT
Galectin Therapeutics
2.47
1.13
84.33%
ABEO
Abeona Therapeutics
5.19
0.27
5.49%
HUMA
Humacyte
0.69
-0.85
-55.13%
VOR
Vor Biopharma
15.87
1.87
13.36%
Silence Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Silence Therapeutics Updates Pipeline, Reports 2025 Financial Results
Negative
Mar 5, 2026
On 5 March 2026, Silence Therapeutics reported fourth-quarter and full-year 2025 results, highlighting clinical progress across its siRNA pipeline and an updated corporate presentation. The company said enrollment in its Phase 2 SANRECO trial of d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.